Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-07-17

Clinical Trial Update: Relapse Prevention Study in Patients With Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 relapse prevention study in schizophrenia has completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Snippet

Sponsor: Vanda Pharmaceuticals | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2023-07-17